Haemodynamics, fluids & transfusion
Tranexamic acid and blood loss in pancreaticoduodenectomy: TAC-PD randomized clinical trial
Primary result · Intraoperative blood lossResult — go to the resultMean difference −42 ml 95% CI −191 to 106Authors' conclusion
Perioperative TXA use did not reduce blood loss during PD.
Study context
- Population
- Adults undergoing planned pancreaticoduodenectomy for biliary, duodenal, or pancreatic diseases202 received intervention and underwent pancreaticoduodenectomy (PD)
- Participants
- 218 adults
- Comparison
- Tranexamic acid (TXA) vs placebo
- TXAn = 108
- Placebon = 110reference
- Primary endpoint
- Blood loss during pancreaticoduodenectomy
Methodological detailspragmatic, multicentre, blinded, placebo-controlled, Randomised September 2019 to May 2021
- Pragmatic
- Multicentre
- Blinded
- Placebo-controlled
- Randomised September 2019 to May 2021
Primary result
Intraoperative blood loss
Mean difference
−42 ml
95% CI −191 to 106
By group
TXA vs Placebo
mean difference −42 ml (95% CI −191 to 106)
As reported in the abstract
Secondary outcomes
Mean, ml
| Outcome | TXA | Placebo | Mean difference (ml) (95% CI) | |
|---|---|---|---|---|
| Blood loss during PD (patients who received intervention and underwent PD) | 667 | 744 | −77 (−226 to 72) | |
| −300−200−1000100Difference, ml (linear scale) |
- Blood loss during PD (patients who received intervention and underwent PD): 202 of 218 patients
Perioperative blood transfusions, operating time, morbidity, mortality
- Comparable between the two groups
Original publication
Tranexamic acid and blood loss in pancreaticoduodenectomy: TAC-PD randomized clinical trial. Br J Surg. Published 16 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →